Press Releases

5/24/2011
United States Patent Office Grants Additional Patent to DxNA for GeneSTAT System
DxNA announces that the USPTO has granted an additional patent to DxNA for the GeneSTAT system: "Rapid Thermocycler WIth Movable Cooling Assembly"

4/30/2010
DxNA Completes H5N1 Test Validation in Vietnam
DxNA announced that it has successfully completed H5N1 test validation in Vietnam at the prestigious National Institute of Veterinary Research. The results are reported on the Joint FAO/IAEA Division website.

12/14/2009
FDA Grants Emergency Use Authorization for DxNA’s GeneSTATTM Integrated PCR-based Influenza Detection System for H1N1 Virus
Groundbreaking 4.5kg “Lab in a BoxTM” to Provide Fast H1N1 Virus Detection St. George, UT (December 14, 2009) - DxNA announced today that the United States Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its 2009 H1N1 influenza virus diagnostic test for use in DxNA’s GeneSTAT® detection platform.

11/13/2009
DxNA GeneSTAT PCR System Successfully Completes Evaluation.
DxNA, a molecular diagnostics company headquartered in St. George, Utah, announced today that the DxNA GeneSTAT PCR system has successfully completed evaluation studies under the direction of a California laboratory supported by the Joint FAO/IAEA Programme in Food and Agriculture.

10/1/2009
DxNA Addresses International Avian Influenza Conference
DxNA Vice President Craig Mosman was invited to address the Regional European Training Course on “Advanced Molecular diagnosis and characterization of Avian Influenza (Bird Flu)” co-sponsored by EU ConFluTech Project held from 21 September to 2 October 2009 at the IAEA...

6/9/2009
DxNA Submits its Rapid Detection Platform Test for H1N1 to FDA
DxNA announced today that it has submitted a request to the FDA for Emergency Use Authorization (EUA) for its GeneSTAT® pathogen platform, for the detection of the H1N1 virus (known as swine flu). EUA allows for the early availability of important diagnostic and therapeutics tools to diagnose, treat, or prevent critical or life-threatening diseases or conditions, when an alternative or approved solution is not available(1).

4/29/2009
DxNA to Use its Rapid Detection Platform to Simplify Testing for H1N1 Flu (Swine Flu)
Company’s 4.5kg “Lab in a Box” Allows for Rapid Onsite Pathogen Detection

3/23/2009
Cyril Boynes, a Noted Malaria Eradication Advocate, Supports the Use of DxNA's GeneSTAT System in Fight Against Malaria
"Pre-qualify the GeneSTAT® Disease Analyzer for the Global Malaria Action Plan (GMAP) for Control, Elimination and Eradication of malaria," noted civil rights and malaria eradication advocate Cyril Boynes writes in a new paper.

12/2/2008
Responding to Pandemic Prevention Urgency, DxNA Meets with World Leaders and the joint FAO/IAEA Division regarding Avian Influenza
The joint FAO/IAEA Division research coordination meeting on The Early and Rapid Diagnosis of Emerging Diseases was held in Beijing, China from November 24-28, 2008.

6/16/2008
DxNA, a Portable, Rapid, Economical, and Precise Genetic Diagnostic Platform, Receives Equity Investment
DxNA has announced an equity investment from Glory Capital, an organization with over 30 years of international business experience with a primary focus on intellectual property.